Lumante Imaging System
Visualization and local staging of bladder cancer during cystoscopy
Key Facts
About Scinvivo
Scinvivo is pioneering a minimally invasive imaging platform based on forward-looking Optical Coherence Tomography (OCT) to revolutionize cancer diagnostics, starting with bladder cancer. Its Lumante system, which has received FDA Breakthrough Device Designation, consists of a single-use catheter and base station, offering micrometer-level resolution to visualize subsurface tissue layers in real-time during cystoscopy. The technology addresses critical unmet needs by enabling precise local staging of tumors and reducing false positives, potentially increasing survival chances and lowering healthcare costs. While the product is not yet cleared for market (CE/FDA), the company is positioned to impact the standard of care in urological oncology.
View full company profile